SPOTLIGHT -
Studies show potential problems, but many questions remain unanswered
New therapeutic targets, drug development for RP
Claris Bio's journey toward treating neurotrophic keratitis
Ocugen completes dosing in second cohort of GARDian clinical trial for Stargardt disease
(EyePod) From idea to impact: Navigating ophthalmic innovation
Study: Virus that causes COVID-19 can penetrate blood-retinal barrier and may damage vision
Bipartisan proposal introduced in US House to address children's vision impairment